Baxalta Now Part Of Shire
Clinical trials sponsored by Baxalta Now Part Of Shire, explained in plain language.
Baxalta was a biopharmaceutical company acquired by Shire, which is now part of Takeda.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Single gene shot could tame hemophilia b bleeding
Disease control OngoingThis study tests a single intravenous dose of a gene therapy called AskBio009 in up to 30 adults with severe hemophilia B. The therapy delivers a working copy of the factor IX gene to help the body produce its own clotting factor. The main goal is to check safety, but researchers…
Phase: PHASE1, PHASE2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Hemophilia drug safety under the microscope: real-world study launched
Knowledge-focused OngoingThis study follows 207 people with hemophilia A who are already taking ADYNOVI/ADYNOVATE to prevent bleeding. Researchers want to see if any long-term side effects appear during normal use. The goal is to gather safety information, not to test if the drug works.
Sponsor: Baxalta now part of Shire • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC